Literature DB >> 15340416

Cancer immunotherapy: moving beyond current vaccines.

Steven A Rosenberg1, James C Yang, Nicholas P Restifo.   

Abstract

Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15340416      PMCID： PMC1435696          DOI： 10.1038/nm1100

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  72 in total

1.  Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.

Authors:  Peter Hersey; Scott W Menzies; Gary M Halliday; Tam Nguyen; Margaret L Farrelly; Chitra DeSilva; Margaret Lett
Journal:  Cancer Immunol Immunother       Date:  2003-11-05       Impact factor: 6.968

2.  Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

Authors:  Steven A Rosenberg; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Suzanne L Topalian; Richard M Sherry; Nicholas P Restifo; John R Wunderlich; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Linda Gritz; Dennis L Panicali; Donald E White
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

3.  Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma.

Authors:  Malcolm S Mitchell; June Kan-Mitchell; Philip R Morrow; Denise Darrah; Vicky E Jones; Matthew F Mescher
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

4.  The first 1000 dendritic cell vaccinees.

Authors:  Derry Ridgway
Journal:  Cancer Invest       Date:  2003       Impact factor: 2.176

5.  Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.

Authors:  Masanori Noguchi; Kazuhiko Kobayashi; Norie Suetsugu; Katsurou Tomiyasu; Shigetaka Suekane; Akira Yamada; Kyogo Itoh; Shinshi Noda
Journal:  Prostate       Date:  2003-09-15       Impact factor: 4.104

6.  Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.

Authors:  Vincenzo Mazzaferro; Jorgelina Coppa; Matteo G Carrabba; Licia Rivoltini; Marcello Schiavo; Enrico Regalia; Luigi Mariani; Tiziana Camerini; Alfonso Marchianò; Salvatore Andreola; Roberto Camerini; Marco Corsi; Jonathan J Lewis; Pramod K Srivastava; Giorgio Parmiani
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

7.  Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

Authors:  Robert H Vonderheide; Susan M Domchek; Joachim L Schultze; Daniel J George; Kara M Hoar; Dih-Yih Chen; Katherine F Stephans; Kenkichi Masutomi; Massimo Loda; Zhinan Xia; Karen S Anderson; William C Hahn; Lee M Nadler
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

Review 8.  Control of autoimmunity by naturally arising regulatory CD4+ T cells.

Authors:  Shohei Hori; Takeshi Takahashi; Shimon Sakaguchi
Journal:  Adv Immunol       Date:  2003       Impact factor: 3.543

9.  Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.

Authors:  Craig L Slingluff; Gina R Petroni; Galina V Yamshchikov; Donna L Barnd; Shannon Eastham; Holly Galavotti; James W Patterson; Donna H Deacon; Sarah Hibbitts; David Teates; Patrice Y Neese; William W Grosh; Kimberly A Chianese-Bullock; Elizabeth M H Woodson; Catherine J Wiernasz; Priscilla Merrill; Jennifer Gibson; Maureen Ross; Victor H Engelhard
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544

10.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307
View more
  903 in total

Review 1.  Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy.

Authors:  Arvind Chhabra
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Authors:  Qifeng Zhou; Haiyan Xiao; Yanjun Liu; Yibing Peng; Yuan Hong; Hideo Yagita; Phillip Chandler; David H Munn; Andrew Mellor; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

3.  The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice.

Authors:  Hussein Sultan; Takumi Kumai; Toshihiro Nagato; Juan Wu; Andres M Salazar; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2019-01-02       Impact factor: 6.968

Review 4.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

5.  Engineering T cells for cancer: our synthetic future.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.

Authors:  S Hong; H Li; J Qian; J Yang; Y Lu; Q Yi
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

7.  Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours.

Authors:  Aslan Mansurov; Jun Ishihara; Peyman Hosseinchi; Lambert Potin; Tiffany M Marchell; Ako Ishihara; John-Michael Williford; Aaron T Alpar; Michal M Raczy; Laura T Gray; Melody A Swartz; Jeffrey A Hubbell
Journal:  Nat Biomed Eng       Date:  2020-04-13       Impact factor: 25.671

8.  Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.

Authors:  Na Qiao; Mao Zhang; Gheath Alatrash; Madhushree Zope; Alexander A Perakis; Pariya Sukhumalchandra; Anne V Philips; Haven R Garber; Celine Kerros; Lisa S St John; Maria R Khouri; Hiep Khong; Karen Clise-Dwyer; Leonard P Miller; Steve Wolpe; Willem W Overwijk; Jeffrey J Molldrem; Qing Ma; Elizabeth J Shpall; Elizabeth A Mittendorf
Journal:  Clin Cancer Res       Date:  2019-01-15       Impact factor: 12.531

9.  Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response.

Authors:  Rebekah K O'Donnell; Rosemarie Mick; Michael Feldman; Satoshi Hino; Yan Wang; Marcia S Brose; Ruth J Muschel
Journal:  Cancer Lett       Date:  2007-06-18       Impact factor: 8.679

10.  Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.

Authors:  Samuel Kim; George Buchlis; Zvi G Fridlender; Jing Sun; Veena Kapoor; Guanjun Cheng; Andrew Haas; Hung Kam Cheung; Xiamei Zhang; Michael Corbley; Larry R Kaiser; Leona Ling; Steven M Albelda
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.